NeoImmuneTech (A950220) Q4 2024 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-I7 as lead candidate in oncology and non-oncology indications.

• No commercial product sales yet; revenue from research services and collaborations.

• Listed on KOSDAQ since 2021 as a technology growth company.

• Significant pipeline in clinical and preclinical stages, including ARS, solid tumors, and CAR-T combinations.

Financial highlights

• 2024 consolidated revenue: $124,917, all from research services.

• Operating loss: $(29.4) million, net loss: $(30.0) million, both improved year-over-year.

• Cash and equivalents at year-end: $23.2 million, down from $53.3 million prior year.

• R&D expenses: $20.5 million (consolidated), $20.3 million (separate), both decreased from prior years.

• Equity: $28.3 million, down 51% from previous year due to accumulated losses.

Outlook and guidance

• Expects continued revenue from research services until NT-I7 achieves FDA approval or out-licensing.

• Focus on licensing deals and cost control to address ongoing losses and cash burn.

• Ongoing efforts to secure government grants and optimize operations for liquidity.